Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Liposarcoma × pemigatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Cholangiocarcinoma 2 Solid Tumor, Miscellaneous 1 Recurrence 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Liposarcoma 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 Gastrointestinal Neoplasms 1

Interventions

Doxorubicin 4 pembrolizumab 3 Specimen Handling 3 toripalimab 2 Ifosfamide 2 Biopsy 2 silmitasertib 1 selinexor 1 peposertib 1 pemigatinib 1 pazopanib 1 palbociclib 1 mirdametinib 1 liposomal doxorubicin 1 fludarabine phosphate 1 fludarabine 1 abemaciclib 1 X-Rays 1 Vincristine 1 Trabectedin 1 Temozolomide 1 Surgical Procedures, Operative 1 Radiotherapy 1 Quality of Life 1 Proton Therapy 1 Neoadjuvant Therapy 1 Magnetic Resonance Spectroscopy 1 Irinotecan 1 Injections 1 Histamine H2 Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06389799 2025-08-28

PERELI

Lund University Hospital

Phase 2 Recruiting

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡